Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shot may slash cholesterol after heart attacks

NCT ID NCT06501443

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding inclisiran (a twice-yearly injection) to standard care lowers LDL cholesterol more than standard care alone in 520 patients who recently had a heart attack, stroke, or urgent heart procedure. Participants are randomly assigned to receive inclisiran plus usual care or usual care alone. The main goal is to measure LDL cholesterol change after 330 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Inclisiran (KJX839) injection

What this could lead to

If it works, this could provide a more effective way to lower cholesterol after a heart attack or stroke, reducing the risk of future events.

What could go wrong

This is a Phase 4 real-world study, so it may confirm known benefits but not produce a breakthrough. Results may vary by country and patient adherence.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ISCHEMIC STROKE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myocardial infarction atherosclerosis atherosclerotic cardiovascular disease coronary artery disorder Hypercholesterolemia hypercholesterolemia, familial, 1 ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERCHOLESTEROLAEMIA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

Locations

  • Novartis Investigative Site

    RECRUITING

    Corrientes, W3400CDS, Argentina

  • Novartis Investigative Site

    RECRUITING

    Salvador, Estado de Bahia, 40170-130, Brazil

  • Novartis Investigative Site

    RECRUITING

    Belo Horizonte, Minas Gerais, 30000, Brazil

  • Novartis Investigative Site

    RECRUITING

    Belo Horizonte, Minas Gerais, 30110-934, Brazil

  • Novartis Investigative Site

    RECRUITING

    Campo Largo, Paraná, 83606-177, Brazil

  • Novartis Investigative Site

    RECRUITING

    Porto Alegre, Rio Grande do Sul, 90560-032, Brazil

  • Novartis Investigative Site

    WITHDRAWN

    Blumenau, Santa Catarina, 89010-500, Brazil

  • Novartis Investigative Site

    RECRUITING

    São José, Santa Catarina, 88103-901, Brazil

  • Novartis Investigative Site

    RECRUITING

    São José, São Paulo, 15015-110, Brazil

  • Novartis Investigative Site

    RECRUITING

    Campina Gde Do Sul, 83430 000, Brazil

  • Novartis Investigative Site

    RECRUITING

    Salvador, 40323-010, Brazil